-
公开(公告)号:US20110224208A1
公开(公告)日:2011-09-15
申请号:US13129311
申请日:2009-11-16
申请人: Dorothée Bardiot , Emilie Blanche , Patrick Chaltin , Mohamed Koukni , Pieter Leyssen , Johan Neyts , Arnaud Marchand , Inge Vliegen
发明人: Dorothée Bardiot , Emilie Blanche , Patrick Chaltin , Mohamed Koukni , Pieter Leyssen , Johan Neyts , Arnaud Marchand , Inge Vliegen
IPC分类号: A61K31/4725 , C07D409/04 , C07D409/14 , C07D405/04 , C07D217/22 , A61K31/472 , C07D401/04 , C07D413/14 , A61K31/5377 , C07D417/04 , A61K31/506 , A61K31/497 , A61P31/14
CPC分类号: C07D409/04 , A61K31/472 , A61K31/4725 , A61K31/497 , C07D217/24 , C07D217/26 , C07D401/04 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/14 , C07D413/04 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14
摘要: The present invention relates to a series of Isoquinolone derivatives which are suitable to treat infections with viruses belonging to the family of the Flaviviridae and more preferably infections with Hepatitis C virus (HCV). The present invention also relates to Isoquinolone compounds for use as a medicine for the prevention or treatment of viral infections, preferably infections with viruses belonging to the family of the Flaviviridae.
摘要翻译: 本发明涉及一系列适用于治疗属于黄病毒科病毒感染的异喹诺酮衍生物,更优选丙型肝炎病毒(HCV)感染。 本发明还涉及用作预防或治疗病毒感染的药物的异喹诺酮化合物,优选为属于黄病毒科的病毒感染。
-
公开(公告)号:US08796273B2
公开(公告)日:2014-08-05
申请号:US13168263
申请日:2011-06-24
IPC分类号: A61K31/501 , A61K31/42 , A61K31/415 , A61K31/422 , A61K31/4184
CPC分类号: A61K31/501 , A61K31/4184 , A61K31/422 , A61K31/506 , A61K45/06 , A61K2300/00 , Y02A50/465
摘要: The present invention relates to the treatment, alleviation, prevention or reduction in the incidence of symptoms, diseases or conditions resulting from or associated with enteroviruses, more particularly the enteroviral infections they cause.
摘要翻译: 本发明涉及治疗,缓解,预防或减少由肠道病毒引起或与肠病毒相关的症状,疾病或病症的发生,特别是其引起的肠道病毒感染。
-
公开(公告)号:US20120022073A1
公开(公告)日:2012-01-26
申请号:US13168263
申请日:2011-06-24
IPC分类号: A61K31/501 , A61P31/14 , A61P31/12
CPC分类号: A61K31/501 , A61K31/4184 , A61K31/422 , A61K31/506 , A61K45/06 , A61K2300/00 , Y02A50/465
摘要: The present invention relates to the treatment, alleviation, prevention or reduction in the incidence of symptoms, diseases or conditions resulting from or associated with enteroviruses, more particularly the enteroviral infections they cause.
摘要翻译: 本发明涉及治疗,缓解,预防或减少由肠道病毒引起或与肠病毒相关的症状,疾病或病症的发生,特别是其引起的肠道病毒感染。
-
公开(公告)号:US20160030447A1
公开(公告)日:2016-02-04
申请号:US14884997
申请日:2015-10-16
申请人: Steven De Jonghe , Ling-Jie Gao , Piet Herdewijn , Jean Herman , Miyeon Jang , Pieter Leyssen , Thierry Louat , Johan Neyts , Christophe Pannecouque , Bart Vanderhoydonck
发明人: Steven De Jonghe , Ling-Jie Gao , Piet Herdewijn , Jean Herman , Miyeon Jang , Pieter Leyssen , Thierry Louat , Johan Neyts , Christophe Pannecouque , Bart Vanderhoydonck
IPC分类号: A61K31/551 , A61K31/5377 , A61K31/519
CPC分类号: A61K31/551 , A61K31/519 , A61K31/52 , A61K31/5377 , C07D473/00 , C07D513/04 , Y02A50/385 , Y02A50/465
摘要: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HN2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HN2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovints.
摘要翻译: 本发明涉及式I,II,III或IV化合物和/或其药学上可接受的加成盐和/或其立体异构体和/或其溶剂合物,其中R1,R2,R3,R4,R5, R6,R7,R8,R9,R11和R12如权利要求1中所定义或如在本发明的描述中详细描述的,以及所述化合物用于治疗或预防病毒感染及其用于制造 治疗或预防病毒感染的药物,特别是属于逆转录病毒科的家族,微病毒科的家族和小核糖核酸病毒科家族的RNA病毒的感染,更优选人免疫缺陷病毒1(HIV1),人类免疫缺陷病毒2 (HN2),丙型肝炎病毒(HCV),登革热病毒和诸如柯萨奇病毒,鼻病毒和脊髓灰质炎病毒的肠道病毒。 本发明还涉及所述化合物的药物组合物和所述药物组合物用于治疗或预防病毒感染的用途。 本发明还涉及所述化合物作为生物活性成分的用途,更具体地说,作为治疗病毒性病症和病理状况的药物,例如但不限于人免疫缺陷病毒1(HIV1),人类免疫缺陷病毒 病毒2(HN2),丙型肝炎病毒(HCV),登革热病毒和诸如柯萨奇病毒,鼻病毒和Poliovints的肠道病毒。
-
公开(公告)号:US09730944B2
公开(公告)日:2017-08-15
申请号:US14884997
申请日:2015-10-16
申请人: Steven De Jonghe , Ling-Jie Gao , Piet Herdewijn , Jean Herman , Miyeon Jang , Pieter Leyssen , Thierry Louat , Johan Neyts , Christophe Pannecouque , Bart Vanderhoydonck
发明人: Steven De Jonghe , Ling-Jie Gao , Piet Herdewijn , Jean Herman , Miyeon Jang , Pieter Leyssen , Thierry Louat , Johan Neyts , Christophe Pannecouque , Bart Vanderhoydonck
IPC分类号: C07D473/00 , A61K31/52 , A61K31/551 , A61K31/519 , C07D513/04 , A61K31/5377
CPC分类号: A61K31/551 , A61K31/519 , A61K31/52 , A61K31/5377 , C07D473/00 , C07D513/04 , Y02A50/385 , Y02A50/465
摘要: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovints.
-
公开(公告)号:US09193741B2
公开(公告)日:2015-11-24
申请号:US13699258
申请日:2011-05-20
申请人: Steven De Jonghe , Ling-Jie Gao , Piet Herdewijn , Jean Herman , Miyeon Jang , Pieter Leyssen , Thierry Louat , Johan Neyts , Christophe Pannecouque , Bart Vanderhoydonck
发明人: Steven De Jonghe , Ling-Jie Gao , Piet Herdewijn , Jean Herman , Miyeon Jang , Pieter Leyssen , Thierry Louat , Johan Neyts , Christophe Pannecouque , Bart Vanderhoydonck
IPC分类号: A61K31/519 , C07D513/04 , A61K31/52 , A61K31/551
CPC分类号: A61K31/551 , A61K31/519 , A61K31/52 , A61K31/5377 , C07D473/00 , C07D513/04 , Y02A50/385 , Y02A50/465
摘要: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.
摘要翻译: 本发明涉及式I,II,III或IV化合物和/或其药学上可接受的加成盐和/或其立体异构体和/或其溶剂合物,其中R1,R2,R3,R4,R5, R6,R7,R8,R9,R11和R12如权利要求1中所定义或如在本发明的描述中详细描述的,以及所述化合物用于治疗或预防病毒感染及其用于制造 治疗或预防病毒感染的药物,特别是属于逆转录病毒科的家族,微病毒科的家族和小核糖核酸病毒科家族的RNA病毒的感染,更优选人免疫缺陷病毒1(HIV1),人类免疫缺陷病毒2 (HIV2),丙型肝炎病毒(HCV),登革热病毒和诸如柯萨奇病毒,鼻病毒和脊髓灰质炎病毒的肠道病毒。 本发明还涉及所述化合物的药物组合物和所述药物组合物用于治疗或预防病毒感染的用途。 本发明还涉及所述化合物作为生物活性成分的用途,更具体地说,作为治疗病毒性病症和病理状况的药物,例如但不限于人免疫缺陷病毒1(HIV1),人类免疫缺陷病毒 病毒2(HIV2),丙型肝炎病毒(HCV),登革热病毒和诸如柯萨奇病毒,鼻病毒和脊髓灰质炎病毒的肠道病毒。
-
公开(公告)号:US20130190297A1
公开(公告)日:2013-07-25
申请号:US13699258
申请日:2011-05-20
申请人: Steven De Jonghe , Ling-Jie Gao , Piet Herdewijn , Jean Herman , Miyeon Jang , Pieter Leyssen , Thierry Louat , Johan Neyts , Christophe Pannecouque , Bart Vanderhoydonck
发明人: Steven De Jonghe , Ling-Jie Gao , Piet Herdewijn , Jean Herman , Miyeon Jang , Pieter Leyssen , Thierry Louat , Johan Neyts , Christophe Pannecouque , Bart Vanderhoydonck
IPC分类号: C07D513/04
CPC分类号: A61K31/551 , A61K31/519 , A61K31/52 , A61K31/5377 , C07D473/00 , C07D513/04 , Y02A50/385 , Y02A50/465
摘要: The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.
摘要翻译: 本发明涉及式I,II,III或IV化合物和/或其药学上可接受的加成盐和/或其立体异构体和/或其溶剂合物,其中R1,R2,R3,R4,R5, R6,R7,R8,R9,R11和R12如权利要求1中所定义或如在本发明的描述中详细描述的,以及所述化合物用于治疗或预防病毒感染及其用于制造 治疗或预防病毒感染的药物,特别是属于逆转录病毒科的家族,微病毒科的家族和小核糖核酸病毒科家族的RNA病毒的感染,更优选人免疫缺陷病毒1(HIV1),人类免疫缺陷病毒2 (HIV2),丙型肝炎病毒(HCV),登革热病毒和诸如柯萨奇病毒,鼻病毒和脊髓灰质炎病毒的肠道病毒。 本发明还涉及所述化合物的药物组合物和所述药物组合物用于治疗或预防病毒感染的用途。 本发明还涉及所述化合物作为生物活性成分的用途,更具体地说,作为治疗病毒性病症和病理状况的药物,例如但不限于人免疫缺陷病毒1(HIV1),人类免疫缺陷病毒 病毒2(HIV2),丙型肝炎病毒(HCV),登革热病毒和诸如柯萨奇病毒,鼻病毒和脊髓灰质炎病毒的肠道病毒。
-
-
-
-
-
-